HeartFlow Announces Its Novel, Non-Invasive FFRct Technology for Coronary Artery Disease Receives Positive Review from Blue Cross Blue Shield

AlixPartners Forecasts: Household Products Could Cost U.S. Manufacturers and Consumers 15% More This Year Due to Resin Shortage

While companies can’t control the market forces at play, they can take action to mitigate the risk and impact of supply chain disruption.

How To Control a Radio Frequency (RF) Process

The radio frequency welding and manufacturing process uses electromagnetic energy and pressure to fuse and permanently bond vinyl, thermoplastic, and coated materials to produce a specific product - all according to customer requirements. Using this RF sealing process, a distinct, one-piece perpetual bond is formulated that is both solid and resistant to ripping or tearing. But how is this process controlled, and with what specific tools? Read on.


BCBS Association’s Evidence Street Concludes HeartFlow FFRct Can Help Patients Avoid Unnecessary Invasive Procedures

HeartFlow, Inc. today announced that Blue Cross Blue Shield (BCBS) Association’s Evidence Street has issued a positive healthcare evidence review of the Company’s HeartFlow® FFRct.

The company reports this non-invasive technology is the first to provide insight into both the extent of coronary artery disease (CAD) and the impact the disease has on blood flow to the heart. It combines anatomic information from a coronary CT angiogram and physiology from HeartFlow FFRct to enable clinicians to select an appropriate and personalized treatment for each patient. The Evidence Street review assessed the technical performance, diagnostic accuracy and clinical utility of HeartFlow FFRct and determined that it provides a meaningful improvement in net health outcome when used to guide the care of patients with stable chest pain who are at intermediate risk of CAD and are being considered for invasive coronary angiography.

John H. Stevens, M.D., chief executive officer of HeartFlow points out, “This marks a major milestone achievement for HeartFlow and our FFRct technology because BCBS’s Evidence Street is among the world’s most rigorous health technology assessments and has significant global reach and influence.” “With BCBS insuring one in three Americans, substantially more patients with suspected CAD in the United States who are part of BCBS plans will be able to access this innovative non-invasive technology. HeartFlow FFRct also could now more rapidly become the standard of care, potentially improving clinical outcomes and saving global healthcare systems billions of dollars annually,” added Stevens.

Evidence Street provides healthcare technology evaluations for the BCBS Association, a national federation of 36 independent, community-based and locally operated Blue Cross and Blue Shield companies that collectively provide healthcare coverage for 105 million Americans. Evidence Street’s assessment of HeartFlow FFRct, which is summarized in a 19-page report, concluded that “CCTA (coronary CT angiogram) with a selective FFRct strategy would likely lead to changes in management that would be expected to improve health outcomes by further limiting unnecessary ICA (invasive coronary angiography) testing.”

Evidence Street joins a growing number of organizations that support the use of HeartFlow FFRct as part of the diagnostic and treatment pathway for CAD. Several payers, including Aetna, which covers more than 46 million lives, have issued positive coverage decisions. In February, the National Institute for Health and Care Excellence (NICE) of the U.K.’s National Health Service, which covers 59 million lives, issued positive guidance, recommending the technology to help determine the cause of stable chest pain in patients. NICE concluded that HeartFlow FFRct is safe, has a high level of diagnostic accuracy, and may avoid the need for invasive coronary angiography, which is associated with risks. NICE further concluded that, compared to all other tests, use of HeartFlow FFRct is the most cost-effective solution as it avoids unnecessary invasive tests and treatment. Additionally, the American College of Cardiology (ACC) and American Heart Association (AHA) recently released updated Appropriate Use Criteria for Coronary Revascularization in Patients with Stable Ischemic Heart Disease, which include the use of HeartFlow FFRct by healthcare providers in determining the appropriateness of revascularizations in many clinical scenarios.



Mediclinic Appoints 2 New Independent Non-Executive Directors

Natalia Barsegiyan and Zarina Bassa will bring significant and diverse skills and experience, complementing those of existing Board members. I am confident they will both be great additions to our Board of Directors.”

Asensus Surgical Appoints Two New Board Members

Asensus Surgical, Inc. (NYSE American: ASXC), a medical device company that is digitizing the interface between the surgeon and the patient to pioneer a new era of Performance-Guided Surgery™, today announced the expansion of its Board of Directors, appointing...

Our Sister Publication: Biotechnology News Magazine

Subscribe to Medical Device News Magazine here.